Michael Abrams - 07 Feb 2025 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Role
Chief Financial Officer
Signature
/s/ Michael Abrams
Issuer symbol
NRXP
Transactions as of
07 Feb 2025
Net transactions value
$0
Form type
4
Filing time
11 Feb 2025, 17:00:05 UTC
Previous filing
22 Nov 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRXP Stock Option (right to buy) Award $0 +50,000 $0.000000 50,000 07 Feb 2025 Common Stock 50,000 $2.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest in three equal annual installments beginning on February 7, 2026.